<DOC>
	<DOCNO>NCT00718757</DOCNO>
	<brief_summary>The purpose study estimate maximum tolerate dose dexamethasone give 5 consecutive day combine fixed dos irinotecan ( give IV , qd x 5 , 2 day , qd x 5 ) vincristine ( give IV , 2 dos total day 1 8 schedule ) child relapse refractory hematologic malignancy . In addition also study pharmacokinetics irinotecan give without dexamethasone patient , evaluate relationship irinotecan pharmacokinetic parameter toxicity describe antitumor effect .</brief_summary>
	<brief_title>Irinotecan , Vincristine , Dexamethasone In Children With Relapsed And/Or Refractory Hematologic Malignancies</brief_title>
	<detailed_description>TREATMENT PLAN Treatment This phase I trial irinotecan , vincristine , dexamethasone administer 2-week period . Each treatment course minimum 21 day first day irinotecan . Cycles may repeat hematologic recovery every 21 day opinion primary physician patient receive benefit chemotherapy . Irinotecan pharmacokinetic study patient perform first course therapy . From 4 18 patient treated determine MTD , irinotecan pharmacokinetics , biologic effect combination chemotherapeutic agent . Drug Dosages Each Course Irinotecan , 20 mg/m2/day IV , Days 1-5 , 8-12 **Dexamethasone Days 6-10 Vincristine 1.5 mg/m2/day IV ( max 2 mg ) , Days 1 , 8 ( patient &lt; 1 year age &lt; 10kg weight : Vincristine 0.05 mg/kg ) CNS Chemotherapy No intrathecal therapy give first course patient . Triple intrathecal chemotherapy ( MHA ) give day 1 subsequent course ( patient eligible ) patient NHL ALL . The age adjust dosage follow : &lt; 12 month Methotrexate 6 mg , Hydrocortisone 12 mg , Ara-C 18 mg 12 -24 month Methotrexate 8 mg , Hydrocortisone 16 mg , Ara-C 24 24-35 month Methotrexate 10 mg , Hydrocortisone 20 mg , Ara-C 30 ≥36 month Methotrexate 12 mg , Hydrocortisone 24 mg , Ara-C 36 **Dose Escalation Dexamethasone The dos irinotecan vincristine fix . The start dose dexamethasone 10 mg/m2/day po divide TID 5 day . Intra-patient dose escalation allow . Dose Level Dose ( mg/m2/day ) Dose Level 1 10 Dose Level 2 20 Dose Level 3 30 If MTD exceed first dose level , subsequent cohort patient treat dose 50 % ( 5 mg/m2 ) low start dose . Inter-Patient Escalation Escalations plan group three patient , three additional patient add first indication DLT . When 3 patient evaluable toxicity complete 3 week therapy dose level without evidence dose-limiting toxicity ( DLT ) subsequent patient may enrol next dose level . If dose-limiting toxicity observe 1 patient initial cohort 3 patient give dose level , 3 additional patient enter dose level . If none additional patient experience DLT ( 1/6 DLT ) , dose level escalate . At time second patient DLT dose level ( ≥ 2 2 6 patient ) , MTD exceed next low dose consider MTD . If MTD exceed first dose level , subsequent cohort patient treat dose 50 % ( 5 mg/m2 ) low start dose . If MTD exceed low level protocol stop . If MTD reach , maximum dose level study consider recommend dose . The exception escalation dose-limiting toxicity diarrhea patient require define MTD , another cohort patient treat dose level addition oral cefixime . If dose-limiting toxicity cohort receives cefixime , dose escalation continue patient receive oral cefixime . Additional Courses Patients may receive additional course opinion primary physician patient receive benefit chemotherapy interval 21 day soon hematologic recovery therapy occur . In addition , patient may receive intrathecal therapy direct primary physician subsequent course . Intra-patient escalation allow .</detailed_description>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Age &lt; equal 21 year time study entry Pathological diagnosis recurrent refractory NonHodgkin 's lymphoma , Hodgkin 's disease , acute lymphoblastic leukemia ECOG performance status &lt; equal 2 ( Lansky playperformance scale &gt; equal 50 % child &lt; 10 year age ) . Has receive chemotherapy previous 2 week . In case rapidly progress disease , criterion may waive consult Principal Investigator , provide patient recover acute effect prior therapy . Hemoglobin &gt; 8 g/dl , absolute neutrophil count &gt; 1000 /mm3 ( without growth factor support ) , platelet count &gt; 50,000/mm3 ( without transfusion support ) unless bone marrow involve tumor leukemia Adequate liver function ( bilirubin &lt; 1.5 x normal age , AST ALT &lt; 3 x normal age ) Adequate renal function ( serum creatinine &lt; 3 x normal age ) No active graftversushost disease ( GVHD ) ongoing treatment GVHD Currently receive cytotoxic investigational drug Pregnant lactating female eligible . Pregnancy test must obtain female postmenarchal . Concomitant use phenytoin , carbamazepine , barbiturate , rifampicin , phenobarbital , azole antifungal , aprepitant , St. John 's Wort allow . Evidence active infection time protocol entry History allergy study medication</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>August 2013</verification_date>
</DOC>